Host metabolism: A target in clinical oncology?

Medical Hypotheses

Volumn 51, Issue 5, 1998, Pages 411-415

  Argiles J M ^a   Lopez Soriano F J ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; LIPID; MUSCLE PROTEIN;

ANEMIA; ANOREXIA; ARTICLE; ASTHENIA; BODY FAT; CACHEXIA; CANCER; CANCER PATIENT; CANCER SURVIVAL; CARBOHYDRATE METABOLISM; DRUG EFFICACY; HUMAN; LIPID METABOLISM; PRIORITY JOURNAL; PROTEIN METABOLISM; WEIGHT REDUCTION;

EID: 0031736537     PISSN: 03069877     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0306-9877(98)90037-8     Document Type: Article

References (37)

1. Zajikek G. Hypothesis: cancer is a metabolic deficiency. Cancer J 1991; 4: 356.
2. Tisdale M J. Cancer cachexia. Anti-Cancer Drugs 1993: 4: 115-125.
3. Copeland E M, Macfayder B V, Dudrick S J. Effect of hyperalimentation in established delayed hypersensibility in the cancer patient. Ann Surg 1976; 184: 60-64.
4. Heber D, Byerley L O, Chi J et al. Pathophysiology of malnutrition in the adult cancer patient. Cancer 1988; 58: 1867-1873.
5. Evans W K, Makuch R, Clamon G H et al. Limited impact of total parenteral nutrition on nutritional status during treatment for small cell lung cancer. Cancer Res 1985; 45: 3347-3353.
6. Lowry S F. Cancer cachexia revisited: old problems and new perspectives. Eur J Cancer 1991; 27: 1-3.
7. Balducci L, Hardy C. Cancer and malnutrition: a critical interaction - a review. Am J Hematol 1985; 18: 911-1003.
8. Beck S A, Tisdole M J. Effect of megestrol acetate on weight loss induced by tumour mecrosis factor-α and a cachexia-inducing (MAC16) in NMRI mice. Br J Cancer 1990; 62: 420-424.
9. Vigano A, Watanawe S, Bruera E. Anorexia and cachexia in advanced cancer patients. Cancer Surveys 1994; 21: 99-115.
10. Kardinal C G, Loprinzi C L, Schaid D J et al. A controlled trial of cyproheptadine in cancer patients with anorexia. Cancer 1990; 65: 2657-2662.
11. Plasse T F, Gorter R W, Krasnow S H, Lane M, Shephard K Y, Wadleigh R G. Recent clinical experience with dronabinol. Pharmacol Biochem Behav 1991; 40: 695-700.
12. Pedersen P L. Tumor mitochondria and the bioenergetics of cancer cells. Prog Exp Tumor Res 1978; 22: 190-274.
13. Tayek J A. A review of cancer cachexia and abnormal glucose metabolism in humans with cancer. J Am Coll Nutr 1992; 11: 455-456.
14. Fanelli F R, Cangiano C, Muscaritoli M, Conversano L, Torelli G F, Cascino A. Tumor-induced changes in host metabolism: a possible marker of neoplastic disease. Nutrition 1995; 11: 595-600.
15. Argilés J M, García-Martínez C, Llovera M, López-Soriano F J. The role of cytokines in muscle wasting: its relation with cancer cachexia. Med Res Rev 12: 637-652.
16. Warren S. The immediate cause of death in cancer. Am J Med Sci 1932; 184: 610-613.
17. Müller O A, von Werder K. Ectopic production of ACTH and corticotropin-releasing hormone (CRH). J Steroid Biochem Mol Biol 1992; 43: 403-408.
18. Pastan I, Fitzgerald D. Recombinant toxins for cancer treament. Science 1991; 254: 1173-1177.
19. Le Bricon T, Gugins S, Cynober L, Baracos V E. Negative impact of cancer chemotherapy on protein metabolism in healthy and tumor-bearing rats. Metabolism 1995; 44: 1340-1348.
20. Gold J. Use of hydrazine sulphate in terminal and pre-terminal cancer patients: results of investigation of new drug (IND) study in 84 evaluable patients. Oncology 1975; 32: 1-10.
21. Chlebowski R T, Bulcavage L, Grosvenor M et al. Hydrazine sulphate influence of nutritional status and survival in non-small cell lung cancer. J Clin Oncol 1990; 8: 9-15.
22. 14C-lysine metabolism in lung cancer patients. Lancet 1987; ii: 241-244.
23. Felig P. Starvation. In: Endocrinology, Vol. 3. New York: Grune & Stratton, 1979: 1927-1940.
24. Stock M J, Rothwell N J. Brown adipose tissue and the response to overfeeding. Biochem Soc Trans 1986; 14: 239-240.
25. Hyltander A, Drott C, Korner V. Elevated energy expenditure in cancer patients with solid tumors. Eur J Cancer 1991; 27: 9-15.
26. Bianchi A, Bruce J. Cooper A L. Increased brown adipose tissue activity in children with malignant disease. Horm Metab Res 1989; 21: 640-641.
27. Oudart H, Calgari C, Andriamampandry M, LeMaho Y, Malan A. Stimulation of brown adipose tissue activity in tumor-bearing rats. Can J Physiol Pharmacol 1995; 73: 1625-1631.
28. Argilés J M, Azcón-Bieto J. The metabolic environment of cancer. Mol Cell Biochem 1988; 81: 3-17.
29. Todorov P, Cariuk P, McDevitt T, Coles B, Fearon K, Tisdale M. Characterization of a cancer cachectic factor. Nature 1996; 22: 739-742.
30. Evans R D, Argilés J M, Williamson D H. Metabolic effects of tumour necrosis factor-α (cachectin) and interleukin-1. Clin Sci 1989; 77: 357-364.
31. Costelli P, Carbó N, Tessitore L et al. Tumour necrosis factor-α mediates changes in muscle protein turnover in a cachectic rat tumour model. J Clin Invest 1993; 92: 2783-2789.
32. Llovera M, Garcia-Martínez C, Agell N, Marzábal M, López-Soriano F J, Argilés J M. Ubiquitin gene expression is increased in skeletal muscle of tumour-bearing rats. FEBS Lett 1994; 338: 311-318.
33. Argilés J M, López-Soriano F J. The ubiquitin-dependent proteolytic pathway in skeletal muscle: its role in pathological states. Trends Pharmacol Sci 1996; 17: 223-226.
34. Tisdale M J. Mechanism of lipid mobilization associated with cancer cachexia: interaction between the polyunsaturated fatty acid, eicosapentaenoic acid, and inhibitory guanine nucleotide-regulatory protein. Prostaglandins Leukotr Essent Fatty Acids 1993; 48: 105-109.
35. Beck S A, Smith K L, Tisdale M J. Anticachectic and antitumour effect of eicosapentaenoic acid and its effect on protein turnover. Cancer Res 1991; 51: 6089-6093.
36. 2-adrenergic agonist (clenbuterol). J Clin Invest 1995; 95: 2367-2372.
37. Costelli P, Llovera M, García-Martínez C, Carbó N, López-Soriano F J, Argilés J M. Enhanced leucine oxidation in rats bearing an ascites hepatoma (Yoshida AH-130) and its reversal by clenbuterol. Cancer Lett 1995; 91: 73-78.